A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112

A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112 After Oral Administration in Healthy and Obese Male Subjects

1. Study Objective: The objective of this phase 1 clinical trial is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and food effect of HSG4112 after oral administration in healthy male subjects.
2. Study Design and Plan: This study is a dose-block randomized, double-blind, placebo-controlled, single and multiple dosing, dose-escalation phase 1 clinical trial. A unique randomization number will be assigned to each subject deemed eligible to participate in the study based on the inclusion/exclusion criteria. Each subject will be randomized to one of the six groups for the single ascending dose (SAD) study or one of the three groups for the multiple ascending dose (MAD) study. Each dose group will consist of ten subjects, and among the ten subjects, eight subjects will be randomized to receive HSG4112 and two subjects will be randomized to receive placebo. The subjects will be studied in a double-blind manner and will receive the investigational product (i.e., HSG4112 or placebo) via once-daily oral administration. The dosing duration for the MAD study is 14 days. When escalating the dose, the Investigator will review all of the available safety data from the preceding dose in a blinded manner to ensure if it is safe to escalate the dose. In order to evaluate safety and tolerability, assessments, such as vital signs, 12-lead electrocardiogram, laboratory test, semen analysis (MAD study only), physical examination, and adverse event monitoring will be performed. Blood samples will be collected to evaluate the pharmacokinetic/pharmacodynamic characteristics of HSG4112.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Drug: Placebo; Drug: HSG4112

• Study Type: Interventional
• Enrollment (Actual): 90
• Phase: Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Daegu, Korea, Republic of, 41944
    • Kyungpook National University Hospital
  • Seoul, Korea, Republic of, 03080
    • Seoul National University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 50 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Able to comprehend and willing to sign an informed consent form approved by the IRB before screening.
2. Males between 19 and 50 years of age at screening.

3. Body mass index (BMI) between 18 and 24.9.

   ☞ BMI (kg/m2) = Body weight (kg) / {Height (m)2}

4. In good health, determined by no clinically significant findings from medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory test at screening, or subjects who are deemed acceptable by the Investigator regardless of the test results.

Exclusion Criteria:

1. Significant history or clinical manifestation of any hepatic, kidney, neurological, immune, respiratory, endocrine, hematological, neoplastic, or cardiovascular disease, or psychiatric disorder (e.g., mood disorder, obsessive-compulsive disorder).
2. History of stomach or intestinal disorders (e.g., Chrons disease, ulcer) or surgeries - not including appendectomy, hemorrhoidectomy, or herniotomy - which may affect the pharmacokinetic or pharmacodynamic evaluation of the investigational product.
3. Significant history or clinical manifestation of hypersensitivity to any drug compound (e.g., licorice, aspirin, antibiotics).

4. One of more of the following laboratory test results at screening:

   • ALT (SGPT) > 60 IU/L
   • Glucose (fasting) > 110 mg/dL or < 70 mg/dL
   • Testosterone <2.49 ng/mL or > 8.36 ng/mL
5. Systolic blood pressure of < 90 mmHg or > 150 mmHg, or diastolic blood pressure of < 60 mmHg or > 100 mmHg as determined by vital signs monitored after resting in sitting position for at least 3 minutes.
6. History of drug/chemical abuse or tested positive in urine drug screen.
7. Use or intend to use any prescription medications/products or phytotherapeutic/herbal/plant-derived preparations within 14 days prior to dosing, or any nonprescription medications/products (i.e., over-the-counter (OTC) drugs), health products, or vitamins within 7 days prior to dosing, unless deemed acceptable by the Investigator.
8. Participation in any clinical study or bioequivalence study involving administration of an investigational drug, including any study investigating HSG4112, within 6 months prior to dosing (i.e., within 6 months of the last dose from the previous study).
9. Whole blood donation within 2 months prior to dosing, plasma/platelet donation within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing.
10. Alcohol consumption of > 20 units/week (1 unit = 10 g of pure alcohol) or unable to abstain from consuming alcohol during the study period.
11. Smoked within 90 days prior to dosing. However, participation is acceptable if the subject has quit smoking at least 90 days prior to dosing.
12. Smoker. However, participation is acceptable if the subject has quit smoking at least 3 months prior to dosing.
13. Ingestion of grapefruit-containing foods or beverages 24 hours prior to dosing until discharge, or unable to abstain from ingesting such foods or beverages during the same period.
14. Unable to abstain from caffeine-containing foods or beverages (e.g., coffee, tea (e.g., black tea, green tea), soft drinks, coffee milk, energy drinks, sports drinks) during the admission period.

15. Unable or unwilling to use acceptable contraceptive methods during the study period.

    ☞ Acceptable contraceptive methods include:

    • Use of an intrauterine device, which has been proven highly effective, by the subject's spouse/partner.
    • Physical contraception for subject or spouse/partner used with chemical sterilization.
    • Surgical sterilization (e.g., vasectomy, hysterectomy, tubal ligation, salpingectomy) of the subject or the subject's spouse/partner.
16. Subjects who, in the opinion of the Investigator, should not participate in this study based on clinical laboratory test results or other reasons.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

17

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: HSG4112 30 mg Single Dose; Single oral dosing of HSG4112 30 mg	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 30 mg Single Dose; Single oral dosing of Placebo 30 mg	Drug: Placebo; Once-daily oral administration
EXPERIMENTAL: HSG4112 60 mg Single Dose; Single oral dosing of HSG4112 60 mg	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 60 mg Single Dose; Single oral dosing of Placebo 60 mg	Drug: Placebo; Once-daily oral administration
EXPERIMENTAL: HSG4112 120 mg Single Dose; Single oral dosing of HSG4112 120 mg	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 120 mg Single Dose; Single oral dosing of Placebo 120 mg	Drug: Placebo; Once-daily oral administration
EXPERIMENTAL: HSG4112 240 mg Single Dose (Fasted); Single oral dosing of HSG4112 240 mg under fasted conditions	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
EXPERIMENTAL: HSG4112 240 mg Single Dose (Fed); Single oral dosing of HSG4112 240 mg under fed conditions	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 240 mg Single Dose; Single oral dosing of Placebo 240 mg	Drug: Placebo; Once-daily oral administration
EXPERIMENTAL: HSG4112 480 mg Single Dose; Single oral dosing of HSG4112 480 mg	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 480 mg Single Dose; Single oral dosing of Placebo 480 mg	Drug: Placebo; Once-daily oral administration
EXPERIMENTAL: HSG4112 720 mg Single Dose; Single oral dosing of HSG4112 720 mg	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 720 mg Single Dose; Single oral dosing of Placebo 720 mg	Drug: Placebo; Once-daily oral administration
EXPERIMENTAL: HSG4112 240 mg Multiple Dose; Once-daily multiple oral dosing of HSG4112 240 mg for 14 days	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 240 mg Multiple Dose; Once-daily multiple oral dosing of Placebo 240 mg for 14 days	Drug: Placebo; Once-daily oral administration
EXPERIMENTAL: HSG4112 480 mg Multiple Dose; Once-daily multiple oral dosing of HSG4112 480 mg for 14 days	Drug: HSG4112; Once-daily oral administration; Other Names: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
PLACEBO_COMPARATOR: Placebo 480 mg Multiple Dose; Once-daily multiple oral dosing of Placebo 480 mg for 14 days	Drug: Placebo; Once-daily oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval	Area under the plasma concentration-time curve of HSG4112 over dosing interval (AUCtau)	Hour 0 to 24
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point	Area under the plasma concentration-time curve from time zero to the last measurable point (AUClast)	Hour 0 to 192
Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112	Maximum plasma concentration of HSG4112 (Cmax)	Hour 0 to 192
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity	Area under the plasma concentration-time curve from time zero to infinity (AUCinf)	Hour 0 to 192
Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112	Time to maximum observed plasma concentration of HSG4112 (Tmax)	Hour 0 to 192
Pharmacokinetic Assessment by Half-Life of HSG4112	Half-life of HSG4112 (T1/2)	Hour 0 to 192
Pharmacokinetic Assessment by Oral Clearance of HSG4112	Oral clearance of HSG4112 (CL/F)	Hour 0 to 192
Pharmacokinetic Assessment by Volume of Distribution of HSG4112	Volume of distribution of HSG4112 (Vd/F)	Hour 0 to 192
Safety and Tolerability Assessment by Number of Participants with Change in Vital Signs	Number of participants with clinically significant change in vital signs including blood pressure (mmHg) measured with blood pressure monitor, heart rate (beats per minute) measured with pulse oximeter, and body temperature (degrees Celcius) measured with thermometer	Up to 3 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Participants with Change in 12-Lead Electrocardiogram	Number of participants with clinically significant change in 12-lead electrocardiogram	Up to 3 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Participants with Change in Laboratory Test	Number of participants with clinically significant change in laboratory test assessed through hematology, blood biochemistry, urinalysis, and blood coagulation test	Up to 3 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Patients with Change in Physical Examination	Number of participants with clinically significant change in physical examination	Up to 3 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Patients with Change in Semen Volume	Pre-to-post examination of semen volume (milliliters) by semen analysis to assess the safety and tolerability of HSG4112	Up to 12 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Patients with Change in Semen White Blood Cells	Pre-to-post examination of semen white blood cells (10^3 per microliter) by semen analysis to assess the safety and tolerability of HSG4112	Up to 12 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Patients with Change in Sperm Count	Pre-to-post examination of sperm count (10^6 per milliliter) by semen analysis to assess the safety and tolerability of HSG4112	Up to 12 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Patients with Change in Sperm Motility	Pre-to-post examination of sperm motility (percent of sperm with normal motility) by semen analysis to assess the safety and tolerability of HSG4112	Up to 12 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Patients with Change in Sperm Morphology	Pre-to-post examination of sperm morphology (percent of normal sperm) by semen analysis to assess the safety and tolerability of HSG4112	Up to 12 weeks from day of last dosing
Safety and Tolerability Assessment by Adverse Event Monitoring	Number of participants with observed adverse events	Up to 12 weeks from day of last dosing
Safety and Tolerability Assessment by Number of Patients with Change in Semen pH	Pre-to-post examination of semen white blood cells (10^3 per microliter) by semen analysis to assess the safety and tolerability of HSG4112	Up to 12 weeks from day of last dosing

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacodynamic Assessment by Change of Biomarkers	Measurement of biomarkers including leptin, adiponectin, insulin, C-peptide (connecting peptide), IL6 (interleukin 6), TNF-alpha (tumor necrosis factor alpha), and CCL2 (C-C motif ligand 2) from baseline to day of last dosing will be combined to assess the weight loss effect of HSG4112	Day 1 and 14 pre-dose

Collaborators and Investigators

• Sponsor: Glaceum
• Collaborators: Seoul National University Hospital; Kyungpook National University Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 23, 2018
• Primary Completion (ACTUAL): May 24, 2021
• Study Completion (ACTUAL): May 24, 2021

Study Registration Dates

• First Submitted: January 19, 2021
• First Submitted That Met QC Criteria: January 29, 2021
• First Posted (ACTUAL): February 1, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 1, 2021
• Last Update Submitted That Met QC Criteria: October 25, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: HSG4112-P1-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No